Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

Conclusion: For the first time, we report a potential association between a C1D15 SULmax of 3 or less on 18F-FDG PET/CT and RFS and OS outcomes in patients with ER-negative, HER2-positive breast cancer receiving neoadjuvant HP alone. If confirmed in future studies, this imaging-based biomarker may facilitate early individualization of therapy.

Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Hennessy, M. A., Leal, J. P., Huang, C.-Y., Solnes, L. B., Denbow, R., Abramson, V. G., Carey, L. A., Liu, M. C., Rimawi, M., Specht, J., Storniolo, A. M., Valero, V., Vaklavas, C., Winer, E. P., Krop, I. E., Wolff, A. C., Cimino-Mathews, A., Wahl, R. L., Tags: Clinical Investigations Source Type: research